APLMW
Apollomics Inc. Warrant
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$0.018
Kõrge
$0.018
Madal
$0.018
Maht
0.00M
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika
Seotud uudised
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor ("EGFRi") to bring in $10 million upfront payment and expand dataset to combination therapyNew interim data for
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung
Seotud aktsiad
HWCPZ
Hancock Whitney Corporation 6.25% Subordinated Notes due 2060
RWAYZ
Runway Growth Finance Corp. 8.00% Notes due 2027
HSY
The Hershey Company
GGG
Graco Inc.
KNX
Knight-Swift Transportation Holdings Inc.
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.